Physician profile
Bryan Patrick Kuns
NPI 1750384814
$9,637.61
in general payments reported to CMS, 2019-2025
36 companies · $1,624 in 2025
The $1,624 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,277 · 2020: $1,417 · 2021: $1,207 · 2022: $1,158 · 2023: $1,100 · 2024: $1,853 · 2025: $1,624.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,577.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,577.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,070.74 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $1,018.14 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $820.93 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $766.64 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $735.95 | 2019-2025 | Jardiance |
| Horizon Therapeutics Plc | $538.71 | 2019-2022 | |
| Abbvie INC. | $511.92 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $476.91 | 2022-2024 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $363.31 | 2019-2023 | Trintellix, Vyvanse |
| Axsome Therapeutics, INC. | $314.30 | 2022-2025 | Auvelity, Sunosi, Symbravo |
| Merck Sharp & Dohme LLC | $311.48 | 2019-2025 | Capvaxive |
| Pfizer INC. | $305.34 | 2019-2024 | |
| Abbott Laboratories | $299.81 | 2024-2025 | Freestyle Libre 3, Thoratec Heartmate 3 Lvas Implant Kit |
| Novartis Pharmaceuticals Corporation | $210.71 | 2019-2024 | |
| Astellas Pharma US INC | $204.68 | 2019-2021 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $193.90 | 2020-2024 | Nexletol |
| Exact Sciences Corporation | $180.65 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Lundbeck LLC | $172.09 | 2025 | Rexulti |
| Amgen INC. | $164.67 | 2019-2025 | Repatha, Otezla, Otezla |
| Janssen Pharmaceuticals, INC | $125.20 | 2019-2022 | |
| Silk Road Medical, INC. | $122.93 | 2024 | Enroute Transcarotid Neuroprotection System, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter, Enroute Transcarotid Stent |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $100.28 | 2020-2025 | Xifaxan, Trulance |
| Biohaven Pharmaceuticals, INC. | $95.50 | 2021 | |
| Idorsia Pharmaceuticals US INC | $91.60 | 2022-2023 | Quviviq |
| Bard Peripheral Vascular, INC. | $89.27 | 2025 | Rotarexs 6 F X 135 Cm |
| Hydrocision, INC. | $77.01 | 2025 | Tenjet |
| Teva Pharmaceuticals USA, INC. | $75.22 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $42.31 | 2024 | |
| Eisai INC. | $27.44 | 2020 | |
| Allergan, INC. | $25.71 | 2019-2020 | |
| Xeris Pharmaceuticals, INC. | $23.94 | 2025 | Gvoke Hypopen |
| Medtronic, INC. | $21.71 | 2025 | Venaseal |
| Cranial Technologies, INC | $15.00 | 2022 | |
| Shire North American Group INC | $14.95 | 2019 | |
| Amarin Pharma, INC. | $14.42 | 2019 | |
| Daiichi Sankyo INC. | $14.24 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Kuns listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.